Idenix Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of drugs for the treatment of human viral diseases. The company’s focus is currently on treating patients with hepatitis C infection. Building on its expertise in nucleoside chemistry and other small molecule chemistry and biology, Idenix is poised to become a leader in antiviral pharmaceuticals. The company’s headquarters are located in Cambridge, Mass. For more information, visit the company’s Web site at www.idenix.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: